Cerebrospinal fluid biomarkers, such as Aβ1-42, Tau and pTau, might be useful in identifying MCI subjects at risk of developing AD (Table 2) [41,42,43,44,45,46]. The gene discussed is MAPT; the disease is Alzheimer disease.